Drug Trial News

RSS

Phase I/II LIBRETTO-001 trial: RET inhibitor achieves durable objective responses across multiple tumors

The highly selective RET inhibitor selpercatinib was well-tolerated and achieved durable objective responses across multiple tumor types in the Phase I/II LIBRETTO-001 trial, according to researchers from The University of Texas MD Anderson Cancer Center.

12 Sep 2022

Phase III ADAURA trial reveals promising results for patients with non-small cell lung cancer

Newly released results from the Phase III ADAURA trial reveal that osimertinib yielded a 5.5-year median disease-free survival in the post-surgical treatment of patients with EGFR-mutated lung cancer, and nearly three in four patients treated with adjuvant osimertinib were disease-free at four years.

12 Sep 2022

ACTG announces the initiation of trial evaluating the safety and efficacy of monkeypox treatment

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, which expanded its focus to conduct research into COVID-19, today announced the initiation of STOMP (Study of Tecovirimat for Human Monkeypox Virus), or A5418, a phase 3, randomized, placebo-controlled, double-blind trial evaluating the safety and efficacy of tecovirimat for the treatment of human monkeypox.

9 Sep 2022

Phase 3 clinical trial commences to evaluate antiviral for monkeypox

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States.

9 Sep 2022

Booster vaccination maintains high efficacy against malaria in African children

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of the candidate malaria vaccine, R21/Matrix-M™ - which previously demonstrated high-level efficacy of 77% over the following 12 months in young west African children in 2021.

9 Sep 2022

Clinical trial begins evaluating alternative strategies to administer the JYNNEOS monkeypox vaccine

A clinical trial evaluating alternative strategies for administering the JYNNEOS monkeypox vaccine to increase the number of available doses has begun enrolling adult volunteers.

8 Sep 2022

NIH animal study combines Paxlovid with Lagevrio against SARS-CoV-2 Delta

In a recent study posted to the bioRxiv* preprint server, researchers at the U.S National Institutes of Health demonstrated the efficacy of molnupiravir and nirmatrelvir, two oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals in the rhesus macaque model, the closest proxy to humans.

7 Sep 2022

Combined stem cell and gene therapy shows promise to treat patients with ALS

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier.

5 Sep 2022

High-quality human clinical trials needed to determine the benefits of CBD for heart disease patients

As cannabidiol (CBD) use rises, high quality randomized clinical trials are needed to determine if anti-inflammatory benefits of CBD for heart disease seen in preclinical data will work in a real-world setting, according to research presented at ACC Latin America 2022 Together with CardioAcademic.

5 Sep 2022

Clinical trial shows efficacy and safety of belimumab in East Asian adults with lupus nephritis

This prespecified subgroup analysis of East Asian adults who participated in a phase 3 clinical trial of belimumab added to standard therapy vs. placebo added to standard therapy for lupus nephritis shows earlier and more sustained improvement in kidney outcomes with the addition of belimumab.

2 Sep 2022

$Research shows benefit of dapagliflozin for heart failure patients regardless of ejection fraction$

Research shows benefit of dapagliflozin for heart failure patients regardless of ejection fraction

Dapagliflozin reduces the risks of death and cardiovascular events in patients with heart failure regardless of ejection fraction, according to late-breaking research presented in a Hot Line session today at ESC Congress 2022.

28 Aug 2022

$SGLT2 inhibitors reduce cardiovascular events among heart failure patients with mildly reduced and preserved ejection fraction$

SGLT2 inhibitors reduce cardiovascular events among heart failure patients with mildly reduced and preserved ejection fraction

An analysis of more than 12,000 patients has found that the SGLT2 inhibitors dapagliflozin and empagliflozin reduce cardiovascular death or hospitalization for heart failure by 20% in heart failure patients with mildly reduced and preserved ejection fraction.

28 Aug 2022

Gout medicine fails to improve cardiovascular outcomes in patients with ischemic heart disease

The gout medicine allopurinol has failed to reduce the primary endpoint of nonfatal myocardial infarction, nonfatal stroke or cardiovascular death in patients with ischaemic heart disease, according to late breaking research presented in a Hot Line session today at ESC Congress 2022.

28 Aug 2022

High-dose influenza vaccination in older adults leads to reductions in hospitalizations, all-cause mortality

In an innovative, pragmatic randomized trial, high-dose influenza vaccination in older adults was associated with a reduction in the risk of death by 49% and in the incidence of hospitalization for influenza or pneumonia by 64% compared with standard-dose vaccination.

28 Aug 2022

Adding acetazolamide to intravenous loop diuretics decreases congestion in patients with acute decompensated heart failure

Acetazolamide added to intravenous loop diuretics decreases congestion within three days in patients with acute decompensated heart failure, according to late breaking research presented in a Hot Line session today at ESC Congress 2022.

28 Aug 2022

Sacubitril/valsartan does not change cognitive function in patients with heart failure

Sacubitril/valsartan does not change cognitive function, compared with valsartan, in patients with heart failure and mildly reduced or preserved ejection fraction, according to late breaking research presented in a Hot Line session today at ESC Congress 2022.

26 Aug 2022

New study investigates a potential treatment for people diagnosed with monkeypox

Previous
1
...
29
30
31
32
33
34
35
...
1143
Next

Drug Trial News

Phase I/II LIBRETTO-001 trial: RET inhibitor achieves durable objective responses across multiple tumors

Phase III ADAURA trial reveals promising results for patients with non-small cell lung cancer

ACTG announces the initiation of trial evaluating the safety and efficacy of monkeypox treatment

Phase 3 clinical trial commences to evaluate antiviral for monkeypox

Booster vaccination maintains high efficacy against malaria in African children

Clinical trial begins evaluating alternative strategies to administer the JYNNEOS monkeypox vaccine

NIH animal study combines Paxlovid with Lagevrio against SARS-CoV-2 Delta

Combined stem cell and gene therapy shows promise to treat patients with ALS

High-quality human clinical trials needed to determine the benefits of CBD for heart disease patients

Clinical trial shows efficacy and safety of belimumab in East Asian adults with lupus nephritis

Research shows benefit of dapagliflozin for heart failure patients regardless of ejection fraction

SGLT2 inhibitors reduce cardiovascular events among heart failure patients with mildly reduced and preserved ejection fraction

Gout medicine fails to improve cardiovascular outcomes in patients with ischemic heart disease

High-dose influenza vaccination in older adults leads to reductions in hospitalizations, all-cause mortality

Adding acetazolamide to intravenous loop diuretics decreases congestion in patients with acute decompensated heart failure

Sacubitril/valsartan does not change cognitive function in patients with heart failure

New study investigates a potential treatment for people diagnosed with monkeypox

Glucokinase activator AZD1656 shows potential benefit for diabetics with moderate to severe COVID-19

Clinical trial offers the best treatment option for patients with sight loss as a result of diabetes

Scientists begin phase 2 clinical trials of lupus pill

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News